Biomarkers to Differentiate Acute Chest Syndrome From Vaso‐Occlusive Crisis in Children With Sickle Cell Disease
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14342 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Karen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Acute Chest Syndrome, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Children's of Alabama, NIEHS NIH HHS, NIDA NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Acute Chest Syndrome (ACS) is the leading cause of death in children with sickle cell disease (SCD) in the US—about half of the children who develop ACS present initially with pain.
Methods
Here, we studied biomarkers to differentiate ACS from vaso‐occlusive crises (VOC) in children with SCD who presented with pain to the emergency department (ED). We conducted a prospective cohort study of consecutive patients who presented to the ED with pain and were discharged with ACS or VOC between March, 2017 and February, 2020.
Results
We identified 7 patients with ACS and 19 patients with VOC. The two groups were comparable in age and sex. All patients with ACS had asthma versus 42% of the VOC group. The ACS group had lower weight and BMI z‐scores. Patients with ACS compared to VOC had significantly higher respiratory rates, lower O 2 saturation, and longer hospital stays. They also had higher white blood cell count, glucose level (> 99 mg/dL), anion gap (> 9 mEq/L), sPLA2 (> 7 pg/mL), IFN‐γ (> 17.8 pg/mL), IL‐10 (1.54 pg/mL), and IL‐12 (> 0.5 pg/mL) levels.
Conclusions
We identified biomarkers associated with ACS development in children with SCD presenting with pain that allow for earlier ACS interventions to reduce mortality and morbidity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
- Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Förderung
- Children's of Alabama
- NIEHS NIH HHS
- NIDA NIH HHS
- National Center on Minority Health and Health Disparities
- NIMHD NIH HHS
- National Institute of Environmental Health Sciences
- National Institute on Drug Abuse
- National Institute on Minority Health and Health Disparities
Zitieren
APA
Wang, K., Olave, N., Aggarwal, S., Oh, J. Y., Patel, R. P., Rahman, A. K. M. F., Lebensburger, J., & Alishlash, A. S. (2025). Biomarkers to Differentiate Acute Chest Syndrome From Vaso‐Occlusive Crisis in Children With Sickle Cell Disease. European Journal of Haematology. https://doi.org/10.1111/ejh.14342
Vancouver
Wang K, Olave N, Aggarwal S, Oh JY, Patel RP, Rahman AKMF, et al. Biomarkers to Differentiate Acute Chest Syndrome From Vaso‐Occlusive Crisis in Children With Sickle Cell Disease. European Journal of Haematology. 2025. doi:10.1111/ejh.14342
BibTeX
@article{Wang2025,
author = {Wang, Karen and Olave, Nelida and Aggarwal, Saurabh and Oh, Joo-Yeun and Patel, Rakesh P and Rahman, A K M Fazlur and Lebensburger, Jeffrey and Alishlash, Ammar Saadoon},
title = {Biomarkers to Differentiate Acute Chest Syndrome From Vaso‐Occlusive Crisis in Children With Sickle Cell Disease},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14342}
}
EUVIMED